Neuropsychiatric bases of the methylphenidate-therapy of the Attention Deficit/Hyperactivity Disorder (ADHD);Neuropsychiatrie des methylphenidat bei der Aufmerksamkeits-Defizit/ Hyperaktivitäts-Störung (ADHS)

Fortschritte der Neurologie Psychiatrie

Volumn 75, Issue 5, 2007, Pages 275-284

  Huber, Markus ^a   Kirchler, E ^b   Niederhofer, H ^b   Gruber, L ^b  

^a Zentrum für Psychische Gesundheit Psychiatrie Sanitätsbetrieb Bruneck   (Italy)

^b NONE

Author keywords

ADHD; Dopamine transporter; Methylphenidate

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MAPPING; HUMAN; MEDICAL RESEARCH; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MAGNETIC RESONANCE IMAGING; METHYLPHENIDATE;

EID: 34250029044     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-932179     Document Type: Review

References (191)

1. Conners CK, Eisenberg L. The effects of methylphenidate on symptomatology and learning in disturbed children. Am J Psychiat 1963; 120: 458-464
2. Millichap JG, Fowler GW. Treatment of "minimal brain dysfunction syndromes": Selection of drugs for children with hyperactivity and learning disabilities. Pediatr Clin North Am 1967; 14 (4): 767-777
3. Barkley RA. A review of stimulant drug research with hypetactive children. J Child Psychol Psychiatry 1977; 18: 137-165
4. Bradley C. The behavior of children receiving benzedrine. Am J Psychiat 1937; 94: 577-585
5. Panizzon L. La preparazione di piridil-e piperidil- arilacetonittili e di alcuni prodotti di trasformazione, pt.1. Helv Chim Acta 1944; 27: 1748
6. AACAP. Practice Parameter for the Use of Stimulant Medication in the Treatment of Children, Adolescents and Adults. J of the American Academy for Child and Adolescent Psychiatry 2002; 41 Suppl.2: 26-49
7. Buitelaar JK, Montgomery SA, Zwieten-Boot BJ van. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 2003; 13 (4): 297-304
8. Swanson JM, Seargent JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP. Attention-deficit disorder and hyperkinetic disorder. Lancet 1998; 351 (9100): 429-433
9. Wender PH. Attention-deficit hyperactivity disorder in adults. Psychiatr Clin North Am 1998; 21 (4): 761-774
10. Spencer TJ, Biederman J, Wilens E, Faraone SV. Overview and Neurobiology of Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry 2002; 63 Suppl. 12: 3-9
11. Retz W, Pajonk FG, Rösler M. Eine Aufgabe für die psychiatrische Forschung und Krankenversorgung - Die Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) im Erwachsenenalter. Psychoneuro 2003; 29: 527-531
12. Steinhausen HC. Attention-deficit hyperactivity disorder in a life perspective. Acta Psychiatr Scand 2003; 107 (5): 321-322
13. MTA Cooperative Group. 14-Month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073-1086
14. NIH. National Institutes of Health Consensus Development Conference Statement-Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 2000; 39: 182-193
15. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, McCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, Toprac MG. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/ Hyperactivity Disorder. Part 1 and II. J Am Acad Child Adolesc Psychiatry 2000; 39 (7): 908-927
16. Vitiello B. Long-term effects of stimulant medication on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11 (1): 25-34
17. Döpfner M, Lehmkuhl G. Evidenzbasierte Therapie von Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). Prax Kinderpsychol Kinderpsychiatr 2002; 51 (6): 419-440
18. Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004; 19 (3): 151-180
19. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2004; 7 (1): 77-97
20. Santosh PJ, Taylor E. Stimulant drugs. Eur Child Adolesc Psychiatry 2000; 9 (1): 27-43
21. Spencer TJ. ADHD treatment across the life cycle. J Clin Psychiatry 2004; 65 Suppl. 3: 22-26
22. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002; 5: 189-202
23. Wilens TE. Drug therapy for adults with attention-deficit hyperactivity-disorder. Drugs 2003; 63 (22): 2395-2411
24. Fröhlich J, Lehmkuhl G. Die medikamentöse Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter. Nervenarzt 2004; 75: 1074-1082
25. Pliszka SR, McCracken JT, Mass JW. Catecholamines in attention deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35 (3): 264-272
26. Biederman J, Faraone SV. Current concepts on the neurobiology of Attention-Deficit/Hyperactivity Disorder. J Atten Disord 2002; 6 Suppl. 1: 7-16
27. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Animals models of attention-deficit/hyperactivity disorder. Brain Res Rev 2003; 42 (1): 1-21
28. Pliszka SR. The neuropsychopharmacology of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57 (11): 1385-1390
29. Oades RD, Sadile AG, Sagvolden T, Viggiano D, Zuddas A, Devoto P, Aase H, Johansen EB, Ruocco LA, Russell VA. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci 2005; 8 (2): 122-131
30. Schachar R, Tannock R, Mariott M, Logan G. Deficient inhibitory control in attention deficit hyperactivity disorder. J Abnorm Child Psychol 1995; 23 (4): 411-437
31. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121 (1): 65-94
32. Pineda D, Ardila A, Rosselli M, Cadavid C, Manchem S, Mejia S. Executive dysfunction in children with attention deficit hyperactivity disorder. Int J Neurosci 1998; 96 (3-4): 177-196
33. Swanson JM. Role of executive function in ADHD. J Clin Psychiatry 2003; 64 Suppl. 14: 35-39
34. Sonuga-Barke EJ. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry 2005; 57 (11): 1231-1238
35. Posner MI, Dehaene S. Attentional networks. Trends Neurosci 1994; 17 (2): 75-79
36. Afifi AK. Basal ganglia: functional anatomy and physiology. Part I. J Child Neurol 1994; 9 (4): 249-260
37. Masterman DL, Cummings JL. Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behaviors. J Psychopharmacol 1997; 11 (2): 107-114
38. Saint-Cyr JA. Frontal-striatal circuit functions: context, sequence, and consequence. J Int Neuropsychol Soc 2003; 9 (1): 103-127
39. Kaiser S, Mundt C, Weisbrod M. Exekutive Konttollfunktionen und Neuropsychiatrische Erkrankungen - Perspektiven für Forschung und Klinik. Fortschr Neurol Psychiatr 2005; 73: 438-450
40. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231 (4735): 258-261
41. Kessler RM, Whetsell WO, Ansari MS, Votaw JR, de Paulis T, Clan ton JA, Schmidt DE, Mason NS, Manning RG. Identification of extrastriatal dopamine D2-receptors in post mortem human brain with (1251) epidepride. Brain Res 1993; 609 (1-2): 237-243
42. Williams GV, Goldmann-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376 (6541): 572-575
43. Hall H, Farde L, Halldin C, Hard YL, Pauli S, Sedvall G. Autotadiographic localization of extrastriatal D2-dopamine receptors in the human brain using (125I)epidepride. Synapse 1996; 23 (2): 115-123
44. Volkow ND, Fowler JS, Gatley SJ, Logan J, Wang GJ, Ding YS, Dewey S. PET evaluation of the dopamine system of the human brain. J Nucl Med 1996; 37 (7): 1242-1256
45. Gerlach M, Gsell W, Kornhuber J, Jellinger K, Krieger V, Pantucek F, Vock R, Riederer P. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal gangliathalamocortical circuits in Parkinson syndrome. Brain Res 1996; 741 (1-2): 142-152
46. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994; 6 (4): 358-370
47. Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 1997; 11 (2): 151-162
48. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002; 67 (1): 53-83
49. Nieoullon A, Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol 2003; 16 Suppl. 2: 3-9
50. Coull JT. Neural correlates of attention and arousal; insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog Neurobiol 1998; 55 (4): 343-361
51. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46 (9): 1234-1236
52. Roessner V, Banaschewski T, Uebel H, Becker A, Rothenberger A. Neuronal network models of ADHD - lateralization with respect to interhemispheric connectivity reconsidered. Eur Child Adolesc Psychiatry 2004; 13 Suppl. 1: 171-179
53. Faraone SV, Biederman J. Neurobiology of attention deficit hyperactivity disorder. Biol Psychiatry 1998; 44 (10): 951-958
54. Sieg KG. Neuroimaging and attention deficit disorder.In: Accardo PJ, Blondis TA, Whitman BY, Stein MA (eds). Attention deficits and hyperactivity in children and adults. New York, Basel: Marcel Dekker; 2000: 73-118
55. Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, Blumenthal JD, James RS, Ebens CL, Walter JM, Zijdenbos A, Evans AC, Giedd JN, Rapoport JL. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002; 288 (14); 1740-1748
56. Durston S. A review of the biological bases of ADHD: what have we learned from imaging studies? Ment Retard Dev Disabil Res Rev 2003; 9 (3): 184-195
57. Roth RM, Saykin AJ. Executive dysfunction in attention-deficit/ hyperactivity disorder: cognitive and neuroimaging findings. Psychiatr Clin North Am 2004; 27 (1): 83-96
58. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry 2005; 57 (11): 1273-1284
59. Seidman LJ, Valera EM, Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57 (11): 1263-1272
60. Willis WG, Weiler MD. Neural substrates of childhood attention-deficit/hyperactivity disorder: electroencephalographic and magnetic resonance imaging evidence. Dev Neuropsychol 2005; 27 (1): 135-182
61. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DB, Sarfatti SE, Vauss YC, Snell JW, Lange N, Kaysen D, Krain AL, Ritchie GF, Rajapakse JC, Rapoport JL. Quantitative brain magnetic resonance imaging in attention deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53 (7): 607-616
62. Casey BJ, Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Schubert AB, Vauss VC, Vaituzis AC, Dickstein DB, Sarfatti SE, Rapoport JL. Implication of right frontostriatal circuitry in response inhibition on attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36 (3): 374-383
63. Hynd GW, Semrud-Clikeman M, Lorys AR, Novey ES, Elipopulus D, Lyytinen H. Corpus Callosum morphology in attention deficit hyperactivity disotder: morphometric analysis of MRI. J Learn Disabil 1991; 24 (3): 141-146
64. Semrud-Clikeman M, Filipek PA, Biederman J, Steingard R, Kennedy D, Renshaw P, Bekken K. Attention deficit hyperactivity disorder: Magnetic resonance imaging morphometric analysis of the corpus callosum. J. Am Acad Child Adolesc Psychiatry 1994; 33 (6): 875-881
65. Giedd JN, Castellanos FX, Casey BJ, Kozuch P, King AC, Hamburger SD, Rapoport JL. Quantitative morphology of the corpus callosum in attention deficit hyperactivity disorder. Am J Psychiatry 1994; 151 (5): 665-669
66. Baumgardner TL, Singer HS, Denkla MB, Rubin MA, Abrams MT, Colli MJ, Reiss AL. Corpus callosum morphology in children with Tourette syndrome and attention deficit hyperactivity disorder. Neurology 1996; 47 (2): 477-482
67. Hynd GW, Hern CL, Novey ES, Eliopulus D, Marshall R, Gonzales JJ, Voeller KK. Attention deficit hyperactivity disorder and asymmetry of the caudate nucleus. J Child Neurol 1993; 8 (4): 339-347
68. Aylward EM, Reiss AH, Reader MJ, Singer HS, Brown JE, Denckla MB. Basal ganglia volumes in children with attention-deficit hyperactivity disorder. J Child Neurol 1996; 11 (2): 112-115
69. Overmeyer S, Bullmore ET, Suckling J, Simmons A, Williams SC, Santosh PJ, Taylor E. Distributed grey and white matter deficits in hyperkinetic disorder: MRI evidence for anatomical abnormality in an attentional network. Psychol Med 2001; 31 (8): 1425-1435
70. Mostofsky SH, Reiss AL, Lockhart P, Denckla MB. Evaluation of cerebellar size in attention-deficit/hyperactivity disorder. J Child Neurol 1998; 13 (9): 434-439
71. Berquin PC, Giedd JN, Jacobson LK, Hamburger SD, Krain AL, Rapoport JL, Castellanos FX. Cerebellum in attention-deficit hyperactivity disorder: a morphometric MRI study. Neurology 1998; 50 (4): 1087-1093
72. Castellanos FX, Giedd JN, Berquin PC, Walter JM, Sharp W, Tran T, Vaituzis AC, Blumenthal JD, Nelson J, Bastain TM, Zijdenbos A, Evans AC, Rapoport JL. Quantitative brain magnetic resonance imaging in girl with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001; 58 (3): 289-295
73. Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann WE. Smaller prefrontal and premotor volumes in boys with attention deficit/ hyperactivity disorder. Biol Psychiatry 2002; 52 (8): 785-794
74. Schrimsher GW, Billingsley RL, Jackson EF, Moore BD. Caudate nucleus volume asymmetry predicts attention-deficit/hyperactivity disorder (ADHD) symptomatology in children. J Child Neurol 2002; 17 (12): 877-884
75. Sowell ER, Thompson PM, Welcome SE, Henkenius AL, Toga AW, Peterson BS. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. The Lancet 2003; 362 (9397): 1699-1707
76. Pueyo R, Maneru C, Junque C, Vendrell P, Pujol J, Mataro M, Estevez-Gonzalez A, Garcia-Sanchez C. Quantitative Signal Intensity Measures on Magnetic Resonance Imaging in Attention-Deficit Hyperactivity Disorder. Cogn Behav Neurol 2003; 16 (1): 75-81
77. Bussing R. Grudnik J, Mason D, Wasiak M, Leonard C. ADHD and conduct disorder: an MRI study ina community. World J Biol Psychiatry 2002; 3 (4): 216-220
78. Hill DE, Yeo RA, Campbell RA, Hart B, Vigil J, Brooks W. Magnetic resonance imaging correlates of attention-deficit/hyperactivity disorder in children. Neuropsychology 2003; 17 (3): 496-506
79. Durston S, Hulshoff Pol HE, Schnack HG, Buitelaar JK, Steenhuis MP, Minderaa RB, Kahn RS, Engeland H van. Magnetic Resonance Imaging of Boys with Attention-Deficit/Hyperactivity Disorder and Their Unaffected Siblings. J Am Acad Child Adolesc Psychiatry 2004; 43 (3): 332-340
80. Bush G, Frazier JA, Rauch SL, Seidmann LJ, Whalen PJ, Jenike MA, Rosen BR, Biederman J. Anterior cingulate cortex dysfunction in attention deficit hyperactivity disorder revealed by fMRI and the Continuing Stroop. Biol Psychiatry 1999; 45 (12): 1542-1552
81. Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SC, Simmons A, Bullmore ET. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry 1999; 156 (6): 891-896
82. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, Gabrieli JD. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci USA 1998; 95 (24): 14494-14499
83. Teicher MH, Anderson CM, Polcari A, Glod CA, Mass LC, Renshaw PF. Functional deficits in basal ganglia of children with attention deficit/ hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat Med 2000; 6 (4): 470-473
84. Durston S, Tottenham NT, Thomas KM, Davidson MC, Egisti IM, Yang Y, Ulug AM, Casey BJ. Differential pattern of striatal activation in young children with and without ADHD. Biol Psychiatry 2003; 53 (10): 871-878
85. Zang YF, Jin Z, Weng XC, Zhang YW, Yang L, Wang YF, Seidman LJ, Faraone SV. Functional MRI in attention-deficit hyperactivity disorder: Evidence for hypofrontality. Brain Dev 2005; 27 (8): 544-550
86. Rubia K, Smith AB, Brammer MJ, Toone B, Taylor E. Abnormal brain activation during inhibition and error detection in medication-naïve adolescents with ADHD. Am J Psychiatry 2005; 162 (6): 1067-1075
87. Zametkin AJ, Nordahl TE, Gross M, King AC, Semple WE, Rumsey J, Hamburger S, Cohen RM. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Eng J Med 1990; 323 (20): 1361-1366
88. Zametkin AJ, Liebenauer LL, Fitzgerald GA, King AC, Minkunas DV, Herscovitch P, Yamada EM, Cohen RM. Brain metabolism in teenagers with attention deficit hyperactivity disorder. Arch Gen Psychiatry 1993; 50 (5): 333-340
89. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A (fluorine-18) Fluorodopa positron emission tomographic study. J Neurosci 1998; 18 (15): 5901-5907
90. Schweitzer JB, Faber T, Kilts CD, Votaw J, Hoffmann JM, Tune L. Regional cerebral blood flow during repeated exposure to vigilance task in adults with attention deficit hyperactivity disorder (Abstract). Soc Neurosci 1995; 21: 1926
91. Mattay VS, Bermann KF, Ostrem JL, Esposito G, Horn JD van, Bigelow LB, Weinberger DR. Dextroamphetamine enhances "neural network- specific" physiological signals: A positron-emission tomography rCBF study. J Neurosci 1996; 16 (15): 4816-4822
92. Schweitzer JB, Lee DO, Hanford RB, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD. A positron emission tomography study of methylphenidate with ADHD. Alterations in resting blood flow and predicting treatment response. Neuropsychopharmacology 2003; 28 (5): 967-973
93. Lou HC, Rosa P, Pryds O, Kanebaek H, Lunding J, Cumming P, Gjedde A. ADHD: increased dopamine receptor availability linked to attention deficit and low neonatal cerebral blood flow. Dev Med Child Neurol 2004; 46 (3): 179-183
94. Schweitzer JB, Lee DO, Hanford RB, Zink CF, Ely TD, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD. Effect of methylphenidate on executive functioning in adults with attention deficit/hypetactivity disorder: normalization of behavior but not related brain activity. Biol Psychiatry 2004; 56 (8): 597-606
95. Lou HC, Henriksen L, Bruhn P. Focal cerebral hypoperfusion in children with dysphoria and/or attention deficit disorder. Arch Neurol 1984; 41 (8): 825-829
96. Lou HC. Henriksen L, Bruhn P. Focal cerebral dysfunction in developmental learning disabilities. Lancet 1990; 335 (8680): 8-11
97. Lou HC, Henriksen L, Bruhn P, Borner H, Nielsen JB. Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch Neurol 1989; 46 (1): 48-52
98. Sieg KG, Gaffney GR, Preston DF, Hellings JA. SPECT brain imaging abnormalities in attention deficit hyperactivity disorder. Clin Nucl Med 1995; 20 (1): 55-60
99. Langleben DD, Austin G, Krikorian G, Ridlehuber HW, Goris ML, Strauss HW. Interhemispheric asymmetry of regional blood flow in prepubescent boys with attention deficit hyperactivity disorder. Nucl Med Commun 2001; 22 (12): 1333-1340
100. Kim BN, Lee JS, Cho SC, Lee DS. Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder. Yonsei Med J 2001; 42 (1): 19-29
101. Langleben DD, Acton PD, Austin G, Elman I, Krikorian G, Monterosso JR, Portnoy O, Ridlehuber HW, Strauss HW. Effects of Methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit/hyperactivity disorder. J Nucl Med 2002; 43 (12): 1624-1629
102. Kim BN, Lee JS, Shin MS, Cho SC, Lee DS. Regional cerebral perfusion abnormalities in attention deficit/hyperactivity disorder. Statistical mapping analysis. Eur Arch Psychiatry Clin Neurosci 2002; 252 (5): 219-225
103. Kaya GC, Pekcanlar A, Bekis R, Ada E, Miral S, Emiroglu N, Durak H. Technetium-99mHMPAO brain SPECT in children with attention deficit/hyperactivity disorder. Ann Nucl Med 2002; 16 (8): 527-531
104. Rohde LA, Roman T, Szobot C, Cunha RD, Hutz MH, Biederman J. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention deficit/hyperactivity disorder. Synapse 2003; 48 (2): 87-89
105. Lorberboym M, Watemberg N, Nissenkorn A, Nir B, Lerman-Sagie T. Technetium 99 m ethylcysteinate dimer single-photon emission computed tomography (SPECT) during intellectual stress to children and adolescents with pure versus comorbid attention deficit/hyperactivity disorder (ADHD). J Child Neurol 2004; 19 (2): 91-96
106. Oner O, Oner P, Aysev A, Kucuk O, Ibis E. Regional cerebral blood flow in children with ADHD: changes with age. Brain Dev 2005; 27 (4): 279-285
107. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354 (9196): 2132-2133
108. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000; 285 (2): 107-110
109. Dresel S, Krause J, Krause KH, la Fougere C, Brinkbaumer K, Kung HF, Hahn K, Tatsch K. Attention deficit hyperactivity disorder: binding of 99mTC-Trodat-l to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 2000; 27 (10): 1518-1524
110. Dyck CH van, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibl JP, Innis RB. Unaltered Dopamine Transporter Availability in Adult Attention Deficit Hyperactivity Disorder. Am J Psychiatry 2002; 159 (2): 309-312
111. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD. Dopamine transporter density in the basal ganglia assessed with (1231) IPT SPET in children with attention-deficit/hyperactivity disorder. Eur J Nucl Med Mol Imaging 2003; 30 (2): 306-311
112. la Fougere C. (99mTC)Trodat-1: Szintigraphische Darstellung des Dopamintransporters im Gehirn bei gesunden Kontrollen, Patienten mit schizophrenen Störungen und Patienten mit Aufmerksamkeitsdefizit/ Hyperaktivitätsstörungen. München: Dissertation an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München-Klinik und Polyklinik für Nuklearmedizin/Ludwig-Maximilians- Universität; 2003: 1-76
113. la Fougere C. US-Society of Nuclear Medicine Pressemitteilung der Jahrestagung Philadelphia, Pennsylvania: Controlling ADHD: German Scientists Use SPECT Imaging to Predict Patient Response to Drug Therapy. 2004: Posted June 22
114. Rosa Neto P, Lou H, Cumming P, Pryds O, Gjedde A. Methyhlphenidate-evoced potentiation of extracellular dopamine in the brain of adolescents with premature birth: correlation with attentional deficit. Ann NY Acad Sci 2002; 965; 434-439
115. Vles JS, Feron FJ, Hendriksen JG, Jolles J, Kroonenburgh MJ van, Weber WE. Methylphenidate Down-Regulates the Dopamine Receptor and Transporter System in Children with Attention Deficit Hyperkinetic Disorder (ADHD). Neuropediatrics 2003; 34 (2): 77-80
116. Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci 2005 Aug 17; 255 (6): 428-431
117. Rosa-Neto P, Lou HC, Cumming P, Pryds O, Karrebek H, Lunding J, Gjedde A. Methylphenidate-evoked changes in striatale dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disotder. Neuroimage 2005; 25 (3): 868-876
118. Feron FJ, Hendriksen JG, Kroonenburg MJ van, Blom-Coenjaerts C, Kessels AG, Jolles J, Weber WE, Vles JS. Dopamine Transporter in Attention-Deficit Hyperactivity Disorder Normalizes After Cessation of Methylphenidate. Pediatr Neurol 2005; 33 (3): 179-183
119. Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 1987; 241 (1): 152-158
120. Ding VS, Fowler JS, Volkow ND, Dewey SL, Wang GJ, Logan J, Gatley SJ, Pappas N. Chiral drugs: comparison of the pharmacokinetics of [11C] d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology 1997; 131 (1): 71-78
121. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002; 6 Suppl. 1: 31-43
122. Capp PK, Pearl PL, Conlon C. Methylphenidate HCL: therapy for attention-deficit hyperactivity disorder. Expert Rev Neurother 2005; 5 (3): 325-331
123. Nielsen JA, Chapin DS, Moore KE. Differential effects of d-amphetamine, beta-phenylethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and the efflux of dopamine metabolites into cerebroventricular perfusates of rats. Life Sci 1983; 33 (19): 1889-1907
124. Schweri MM, Skolnick P, Rafferty MF, Rice KC, Janowsky AJ, Paul SM. (3H)Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenyl ethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J Neurochem 1985; 45 (2): 1062-1070
125. Gatley SJ, Pan D, Chen R, Chaturvedi G, Ding YX. Affinities of methylphenidate derivates for dopamine, norepinephrine and serotonin transporters. Life Sci 1996; 58 (12): 231-239
126. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine: comparison with amphetamine.J Neurochem 1997; 68 (5): 2032-2037
127. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155 (10): 1325-1331
128. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21 (2):RC121: 1-5
129. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, Ding YS, Gatley SJ, Gifford A, Zhu W, Swanson JM. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002; 43 (3): 181-187
130. Iversen LL. Role of transmitter uptake mechanism in synaptic neurotransmission. Br J Pharmacol 1971; 41 (4): 571-591
131. Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 1991; 254(5031): 576-578
132. Kuhar MJ. Recent biochemical studies of dopamine transporter - a CNS drug target. Life Sci 1998; 62 (17-18): 1573-1575
133. Schenk JO. The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate. Prog Drug Res 2002; 59: 111-131
134. Bannon MJ. The dopamine transporter: role in neurotoxiticity and human disease. Toxicol Appl Pharmacol 2005; 204 (3): 355-360
135. Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougerty DD, Bonab AA, Fischman AJ. In vivo neuroreceptor imaging in attention-deficit/ hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 2005; 57 (11): 1293-1300
136. Amara SG, Kuhar MJ. Neurotransmitter transportets: recent progress. Annu Rev Neurosci 1993; 16: 73-93
137. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in human brain with technetium-99mTRO-DAT-1. Eur J Nucl Med 1996; 23 (11): 1527-1530
138. Dresel S, Kung MP, Plossl K, Meegalla SK, Kung HF. Pharmacological effects of dopaminergic drugs on in vivo binding of (99 m Tc) Trodat-1 to the central dopamine transporters in rats. Eur J Nucl Med 1998; 25 (1): 31-39
139. Mozley PD, Stubbs JB, Plossl K, Dresel SH, Barraclough ED, Alavi A, Araujo LI, Kung HF. Biodistribution and dosymetry of Trodat-1: a technetium-99m tropane for imaging dopamine transporters. J Nucl Med 1998; 39 (12): 2069-2076
140. Kugaya A, Fujita M, Innis RB. Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann Nucl Med 2000; 14 (1): 1-9
141. Piccini PP. Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003; 18 Suppl. 7: 3-8
142. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94 (1): 127-152
143. Solanto MV. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 2002; 130 (1-2): 65-71
144. Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2003; 27 (7): 605-613
145. Cook EH Jr, Stein MA, Krasowsky MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL. Association of attention deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995; 56 (4): 993-998
146. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of association between attention deficit/hyperactivity disorder and a dopamine transporter polymorphism. MoI Psychiatry 1997; 2 (4): 311-313
147. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, Cleveland HH, Sanders ML, Gard JM, Stever C. Association and linkage of the dopamine transporter gene and attention deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 1998; 63 (6): 1767-1776
148. Daly G, Hawi Z, Fitzgerald M, Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry 1999; 4 (2): 192-196
149. Roman T, Rohde LA, Hutz MH. Polymorphism of the dopamine gene: influence response to methylphenidate in attention deficit-hyperactivity disorder. Am J Pharmacogenomics 2004; 4 (2): 83-92
150. Kent L. Recent advances in the genetics of attention deficit hyperactivity disorder. Curr Psychiatr Rep 2004; 6 (2): 143-148
151. Bobb AJ, Castellanos FX, Addington AM, Rapoport JL. Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B Neuropsychiatr Genet 2005; 132 (1): 109-125
152. Cheon KA, Ryu YH, Kim JW, Cho DY. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention-deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 2005; 15 (1): 95-101
153. Mill J, XU X, Ronald A, Curran S, Price T, Knight J, Craig I, Sham P, Plomin R, Aherson P. Quantitative trait locus analysis of candidate gene alleles associated with attention-deficit hyperactivity disorder (ADHD) in five genes: DRD4, DATI, DRD5, SNAP-25 and 5HT1B. Am J Med Genet B Neuropsychiatr Genet 2005; 133 (1): 68-73
154. Feng Y, Wigg KG, Makkar R, Ickowicz A, Pathare T Tannock R, Roberts W, Malone M, Kennedy JL, Schachar R, Barr CL. Sequence variation in the 3′-untranslateted region of the dopamine transporter gene and attention-deficit hyperactivity disorder (ADHD). Am J Med Genet B Neuropsychiatr Genet 2005; 139 (1): 1-6
155. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 2005; 57 (11): 1367-1373
156. Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 2003; 27 (7): 615-621
157. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57 (11): 1410-1415
158. O'Donell P. Dopamine gating of forebrain neural ensembles. Eur J Neurosci 2003; 17 (3): 429-435
159. Kiyatkin EA, Rebec GV. Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats. J Neurophysiol 1996; 75 (1): 142-153
160. Koob GF. Hedonic valence, dopamine and motivation. Mol Psychiatry 1996; 1 (3): 186-189
161. Jonkman LM, Kemmer C, Verbaten MN, Koelega HS, Camferman G, Gaag RJ, Buitelaar JK, Engeland H van. Effects of methylphenidate on event related potentials and performance of attention-deficit hyperactivity disorder children in auditory and visual selective attention tasks. Biol Psychiatry 1997; 41 (6): 690-702
162. Moll GH, Heinrich H, Trott GE, Wirth S, Rothenberger A. Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate. Neurosci Lett 2000; 284: (1-2): 121-125
163. Moll GH, Heinrich H, Rothenberger A. Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attention deficit hyperactivity disorder. Acta Psych Scand 2003; 107 (1): 69-72
164. Hawk LW Jr, Yartz AR, Pelham WE Jr, Lock TM. The effects of methylphenidate on propulse inhibition during attend and ignored prestimuli among boys with attention-deficit hyperactivity disorder. Psychopharmacology (Berl) 2003; 165 (2): 118-127
165. Shafritz KM, Marchione KE, Gore JC, Shaywitz SE, Shaywitz BA. The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. Am J Psychiatry 2004; 161 (11): 1190-1197
166. Carey MB, Diewald LM, Esposito FJ, Pellicano MP, Gironi Carnevale UA, Sergeant JA, Papa M, Sodile AG. Differential distribution, affinity and plasticity of dopamine D1 and D2 receptors in the target sites of the mesolimbic system in an animal model of ADHD. Behav Brain Res 1998; 94 (1): 173-185
167. Ilgin JV, Senol S, Gucuyener K, Gokcora N, Sener S. Is increased D2 receptor availability associated with response to stimulant medication in ADHD. Dev Med Child Neurol 2001; 43 (11): 755-760
168. Seeman P, Madras B. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav Brain Res 2002; 130 (1-2): 79-83
169. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999; 13 (4): 337-345
170. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoreceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct 2005; 1 (1): 2
171. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003; 160 (11): 1909-1918
172. Federici M, Geracitano R, Bernardi G, Mercuri NB. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Biol Psychiatry 2005; 57 (4): 361-365
173. Elliott JM, Beveridge TJ. Psychostimulants and monoamine transporters: upsetting the balance. Curr Opin Pharmacol 2005; 5 (1): 94-100
174. Viggiano D, Vallone D, Sodile A. Dysfunctions in dopamine and ADHD: evidence from animals and modelling. Neural Plast 2004; 11 (1-2): 97-114
175. Shi WX, Pun CL, Zhou Y. Psychostimulants induce low-frequency oscillations in the firing activity of dopamine neurons. Neuropsychopharmacology 2004; 29 (12): 2160-2167
176. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57 (11): 1397-1409
177. Dyck CH van, Saibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB. Age related decline in striatal dopamine transporter binding with iodine-beta-CIT SPECT. J Nucl Med 1995; 36 (7): 1175-1181
178. Mozley PD, Kim HJ, Gur RC, Tatsch K, Muenz LR, McElgin WT, Kung MP, Mu M, Myers AM, Kung HF. Iodine-(123i)IPT SPECT imaging of CNS dopamine transporters: non linear effect of normal aging on striatal uptake values. J Nucl Med (1996)-37; (12): 1965-1970
179. Meng SZ, Ozawa Y, Itoh M, Takashima S. Developmental and age related changes of dopamine transporters, and dopamine D1 and D2 receptors in human basal ganglia. Brain Res 1999; 843 (1-2): 136-144
180. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields SD, Gur R. Dopamine transporter decrease with age. J Nucl Med 1996; 37 (4): 554-559
181. Dyck CH van, Seibl JP, Malison RT, Lamelle M, Zoghbi SS, Baldwin RM, Innis RB. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002; 10 (1): 36-46
182. Erixon-Lindroth N, Farde L, Wahlin TB, Sovago J, Halldin C, Backman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res 2005; 138 (1): 1-12
183. Polanczyk G, Zeni C, Genro JP, Roman T, Hutz MH, Rohde LA. Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics 2005; 6 (3): 225-234
184. Purper-Quakil D, Wohl M, Mouren MC, Verpillat P, Ades J, Gorwood P. Meta-analysis of family-based association between the dopamine transporter gene and attention deficit hyperactivity disorder. Psychiatr Genet 2005; 15 (1): 53-59
185. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005; 57 (3): 229-238
186. Janowsky A, Mah C, Johnson RA, Cunningham CL, Philipps TJ, Crabbe JC, Eshleman AJ, Belknap JK. Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice. J Pharmacol EXP Ther 2001; 298 (2): 634-643
187. Buck K, Lischka T, Dorow J, Crabbe J. Mapping quantitative trait loci that regulate sensitivity and tolerance to quinpirole, a dopamine mimetic selective for D(2)/D(3) receptors. Am J Med Genet 2000; 96 (5): 696-705
188. Greenwood TA, Kelose JR. Promotor and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 2003; 82 (5): 511-520
189. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005; 57 (11): 1215-1220
190. Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005; 21 (2): 195-206
191. Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJ. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry 2005; 57 (11): 1224-1230